Tolerability of the Low-Affinity, Use-Dependent NMDA Antagonist AR-R15896AR in Stroke Patients

Completed

Phase 2 Results

Summary of Purpose

To establish the highest safe and tolerated loading and maintenance dosing regimen of AR-R15896AR in acute ischemic stroke patients and to determine the plasma concentrations of AR-R15896AR with which these were associated.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 9 February 2001.

Unavailable Unavailable Unavailable Unavailable Unavailable Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Basics

Interventions

Sponsors

  • AstraZeneca

Trial Design

Double-blind, randomized, placebo-controlled trial of 175 patients at 5 centers. The trial consisted of four parts: Part 1; a series of increasing loading doses. Part 2; a comparison of selected doses from part 1. For parts 3 and 4 of this study, the loading dose was fixed for all subjects receiving active drug.

Contacts

  • Prof Kennedy R. Lees, University Department of Medicine and Therapeutics, Gardiner Institute, Western Infirmary, Glasgow G11 6NT, UK.

    kr.lees@clinmed.gla.ac.uk